Strong Revenue Growth
Product revenue increased 97% to $4.7 million in the first half of fiscal 2025 compared to the same period in fiscal 2024.
Significant Improvement in Gross Margins
Product gross margins increased to 57.9% in the first half of fiscal 2025, more than doubling from the first half of fiscal 2024.
Successful Capital Raise
The company raised $8.2 million in net proceeds from a successful capital raise, ensuring funding through at least fiscal 2026.
Positive Clinical Outcomes
Majority of patients treated with the OneRF ablation system are now seizure free, with one patient being seizure free for almost an entire year.
Expansion into New Applications
Filed a 510(k) submission with the FDA for the OneRF trigeminal nerve ablation system ahead of schedule, with potential revenue generation by late 2025.